| |

About the
Hair Loss
Clinic
Male Hair
Loss &
Thinning
Hair
Female Hair
Loss &
Thinning
Hair
Hair Loss Article Resource Center
Client Testimonials and
Photo Gallery
Free Hair
Loss
Evaluation
and
Consultation
Our
Location
Contact Us
|

It's easy to get expert advice
and answers to your
questions and concerns.
|
|
|
|

HAIR LOSS IN CHILDREN AND ADOLESCENTS
by Tony Pearce RN.
Specialist Trichologist, National Trichology Services
There are many
congenital conditions that potentially affect normal hair
growth, but it’s thankfully infrequent for a child to be
troubled with anything more than hair fall of a temporary kind.
When problems do arise most can be treated successfully with
simple alterations to the child’s diet and/or hair care routine.
The most common paediatric hair loss conditions that
trichologists or other health professionals would see are
outlined below.
“Loose anagen syndrome” is a temporary disorder of connective
tissue competency where the hair can be painlessly pulled from
the scalp with little effort. It presents as ‘diffuse’ (all
over) hair loss, and is more commonly seen in fair-haired girls
between the ages of 2 and 9 years.
When visually inspecting the hair shaft, no bulb or root sheath
can typically be seen. Microscopic examination reveals a bent
hair shaft above a shrunken, under-developed or
‘sideways-twisted’ bulb.
Loose anagen syndrome is generally resolved with a short course
of mineral therapy. The present regime is silica 33mg and
calcium fluoride 0.5 mcg three times daily.
“Fail to grow” scalp hair is thought to be a temporary delay in
the growth response mechanism. Typically the child is female
between the ages of 2 and 9 years, with fine hair of thin
density. Presenting parents usually complain that the youngster
has never had a haircut, because her hair has
never grown beyond collar-length! The problem is frequently
corrected with zinc and iron supplements at an appropriate
dosage for the child’s age. Increasing dietary protein intake
would also assist regrowth.
Even without treatment intervention, both problems will usually
recover by the time the child has reached puberty.
When poor dietary habits are extreme or have continued for a
prolonged time, hair breakage, dull, dry hair, or even hair loss
may eventually result. Teenage girls are most commonly ‘at risk’
here with “fad” dieting or inadequate consumption of iron-rich
food sources. Simple advice on the value of the five food groups
and commonsense eating habits is usually enough. A
multi-vitamin/mineral supplement taken for 3-4 months can assist
nutrition until a pattern of healthy eating is secured.
Alopecia areata may present in susceptible children of any
age, and progress to the more severe forms where all
body hair is lost. Alopecia areata is an inherited ‘autoimmune’
condition, which means the affected person’s body is reacting
against itself. This disorder is more often seen in dark-haired
and Asian people, whilst 2-5% of children who develop alopecia
are found to be gluten intolerant (the main protein of wheat).
Although anyone who develops alopecia has a genetic
predisposition to do so, it’s believed that some “trigger”
initiates its presentation. This might be chronic emotional
stress or severe shock, illness, vaccinations, or a
chemical/foreign substance not previously exposed to. In adults,
alopecia areata is closely linked to problems of the thyroid
gland, vitiligo, and Sjogren’s syndrome, whilst periodontal
disease, chronic tonsillitis/sinusitis, or head injury are also
thought to be precipitating factors.
Recently, Israeli researchers have revealed that the body’s
white blood cells may be reacting against the pigment
cells within the hair shaft. That’s why hair regrowth in
alopecia areata is nearly always white i.e.; lacking any colour
pigment.
Where alopecia develops in early childhood, it sometimes shows a
tendency to become more intractable and less responsive to
treatment. Severe alopecia areata can be very destructive
psychologically, so investigations as to a possible cause, and
treatment, should be undertaken without delay.
At the same the treating practitioner should encourage an
optimistic approach to the young patient’s setback. Whilst
treatments for alopecia areata are currently palliative and
probably do not ultimately alter its course,
complete hair regrowth can sometimes occur even in those with
100% scalp hair loss.
Existing treatment for alopecia areata involve the use of
‘immunomodulators’ alone or in combination with biologic
response modifiers such as Minoxidil topical solution.
Topical,
intralesional, or oral corticosteroids, as well as contact
sensitisers (Anthralin, DPCP) are the common immunomodulators.
"Next generation" topical immunomodulators such as 'Protopic' or
'Prograf' (tacrolimus) are gaining increasing favour with
Dermatologists for the treatment of intractable alopecia and
psoriasis.
L-tyrosine amino acid is also an immunomodulation therapy that
trichologists have successfully used in treating autoimmune
diseases that affect the hair. Tyrosine helps reduce the skin’s
neuropeptides, which in turn decreases lymphocytic (white blood
cell) infiltrate surrounding the hair follicle.
Whilst Tyrosine is considered a very safe oral supplement, it’s
contra-indicated in persons with a history of epilepsy. Migraine
headache sufferers are advised to use caution as Tyrosine can
induce headaches in some and relieve them in others.
The current topical therapy considered most appropriate for
children less than ten years of age is 5% Minoxidil solution in
combination with a mid-potency cortisone or Anthralin 0.5-1%
cream. Anthralin may be applied as a “short contact” therapy for
30 –60 minutes each evening, or left on the scalp overnight.
Treatment response should become evident within 2-3 months, and
the routine maintained for about six months for maximum benefit.
Minoxidil is the only topical solution
medically approved to stimulate follicle hair growth.
Prescription formulas that are propylene glycol-free and contain
absorption additives are usually more effective, and with less
potential side effects than the commercially purchased brands.
Photo-biotherapy such as “soft” laser light can also promote an
immunomodulating response. These are non-UV light
sources, and their treatment potential for alopecia areata is
continuing to be evaluated.
For parents who are opposed to topical prescription medications
being used on their children, one Scottish study found that an
essential oil (aromatherapy) combination had some success in the
treatment of alopecia areata. Most importantly this trial
reported significantly fewer adverse effects than is usually
associated with conventional treatments.
Traction alopecia is as the name implies, hair loss that occurs
when the hair is held tightly under tension or “traction”,
causing the hair shaft to be eventually extracted from the
follicle. Traction alopecia is regarded as mechanical hair loss,
and is predominantly seen in females who continually pull their
hair back in buns or ponytails. Here the problem presents as a
‘thinning’ of the hair behind the front hairline margins. This
type of hair loss is also regularly seen with braiding or
‘dreadlock’ hairstyles.
Provided the styling practice is identified and redressed
early, the lost hair will recover. A short course of 5%
Minoxidil topical solution together with some mineral
supplements often helps stimulate follicle hair growth.
Trichologists are now seeing increasing numbers young males
and females with androgenetic alopecia (genetic
‘patterned’ hair loss). Developing this inherited complaint can
be quite devastating for the adolescent in terms of their
self-confidence, and the youth’s parents who often
express feelings of guilt for their child’s affliction.
It cannot be overstated how important it is to refer these young
clients and their parents to a qualified trichologist or family
doctor, who can provide them with accurate information on the
availability of effective approved medication. By doing this,
these families are less vulnerable to the “slick” advertising
promises of commercial hair loss centres that currently ask many
thousands of dollars “up-front” for very dubious treatment
programmes.
The present treatment regime for males is the combined use of
Minoxidil topical solution with Finesteride, a prescription
medication taken orally. Minoxidil should be consistently used
for at least 6 months before assessing its effectiveness. In
clinical trials Finesteride 1mg was shown to stabilise genetic
hair loss in about 60-80% of males.
After aesthetically satisfying hair density has returned,
Minoxidil may be withdrawn but Finesteride should be continued
for as long as the patient wishes to retard their androgenetic
progression.
In my experience the herbal 5-alpha reductase inhibitor, Saw
Palmetto (Serenoa Serrulata), is ineffective as a stabiliser of
androgenetic alopecia in males under 40-45 years of age.
Four or five decades ago female androgenetic alopecia was mostly
limited to elderly women. It’s now not uncommon to see girls as
young as 14-16 years presenting with this complaint.
Female androgenetic alopecia begins as a progressive
thinning-out of the top, temple and/or crown areas of the scalp.
Occipital hair density is usually unaffected unless there is an
underlying nutritional or metabolic disturbance. Unlike men’s
genetic hair loss, not all the hair follicles across the top of
a woman’s scalp are affected – thus ‘thinning’ of
the hair density occurs rather than total baldness.
Characteristic signs and symptoms should reveal the nature of
the problem, but scalp biopsy still remains the definitive
diagnosis.
A careful history and visual assessment of the patient should be
conducted to exclude ‘androgenetic virilising’.
Virilising occurs when increased androgen (male hormone)
production is triggered from the woman’s ovaries or adrenal
glands. The problem may arise in a combination of symptoms that
include hair thinning through the frontal/temple areas of the
scalp, excessive facial/scalp oiliness, increased facial/body
hair, and menstrual irregularity.
These young women should always be referred to their family
doctor for specialist investigations.
Androgenetic hair loss in women is best treated with a
combination therapy of 5% Monoxidil solution, and some form of
oral hormonal medication taken for about 12 months. Prescription
antiandrogens such as ‘Androcur’ or ‘Aldactone’ help to
stabilise the problem by suppressing androgenetic activity.
Whilst taking these drugs, women of childbearing age should
always be on contraceptive medication to prevent pregnancy.
The oral contraceptive Diane 35 ED is also quite useful in the
treatment of androgenetic virilising. However Diane’s efficacy
appears least effective for stabilising genetic
hair thinning because its antiandrogen strength is only 1/25th
the daily dosage required.
A woman’s suitability for Androcur, Aldactone or ‘Diane’ would
need to be assessed by her medical practitioner.
Finally, “trichotillomania” is a somewhat uncommon condition
where the child plucks his or her own hair from the scalp. It’s
often an unconscious act whilst concentrating or ‘day-dreaming’.
Sometimes though it’s the result of underlying anxiety in the
child from a stressful home, school, or other social situation.
Affected areas have a ragged, uneven appearance where much hair
breakage or empty hair follicles are evident. The crown area,
behind the ears, or the opposite side of the scalp
to the dominant hand is usually the area that’s
most ravaged.
As with many habits, trichotillomania can be a difficult
mannerism to arrest. Where the problem has existed for a number
of years, psychotherapy, hypnosis, and/or antidepressant drugs
are often used as treatments.
About the Author:
Tony Pearce is a Specialist Trichologist
& Registered Nurse. He is a founding member
of the Society for Progressive Trichology &
the official lecturer for Analytical
Reference Laboratory (ARL) for hair loss &
hormone imbalance. He is the Clinical
Director for Trichology of Virginia/DC in
the United States. In Australia he can be
contacted on 02 9542 2700, or through his
website at
www.hairlossclinic.com.au.
Copyright Anthony Pearce
2005. *References for this article available on request
|
|